<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059991</url>
  </required_header>
  <id_info>
    <org_study_id>ARIVA_me17Berger</org_study_id>
    <nct_id>NCT04059991</nct_id>
  </id_info>
  <brief_title>Antibodies in Repeated Influenza Vaccination (ARIVA) Study</brief_title>
  <acronym>ARIVA</acronym>
  <official_title>Antibodies in Repeated Influenza Vaccination (ARIVA) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine
      design. The current influenza vaccination strategy of yearly vaccination with adapted strains
      aims to maximally diversify the antibody immune response to prevent viral escape. There is,
      however, growing evidence, that repeated vaccination with very similar viral proteins might
      limit, instead of broaden, diversification and thereby reduce vaccine efficacy.

      The ARIVA Study prospectively studies the immunological impact of repeated influenza
      vaccination on viral variant recognition and antibody responses in healthy subjects
      cross-sectionally and over three consecutive vaccination seasons.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Influenza specific Antibody Responses</measure>
    <time_frame>Change between baseline and 28 days post-vaccination will be compared</time_frame>
    <description>Hemagglutination titers against different H3N2 Influenza strains will be measured and compared between study subjects stratified by number of previous vaccinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasmablast generation</measure>
    <time_frame>Day 7 post-vaccination</time_frame>
    <description>Frequency of plasmablasts in the peripheral blood will be assessed and compared between study subjects stratified by number of previous vaccinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCR Repertoire composition</measure>
    <time_frame>Cross sectional comparison of the BCR repertoire characteristics day 0 and day 28</time_frame>
    <description>Sorted B cell subsets will be sequenced to define the BCR repertoire. Subjects will be compared stratified by vaccination status</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Vaccine Response Impaired</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccination</intervention_name>
    <description>Only subjects vaccinated against influenza will be enrolled. The study itself is observational</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood mononuclear cells, serum and RNA is collected
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  influenza vaccination (QIIV) independent of the study

          -  age &gt;18 yo

        Exclusion Criteria:

          -  no vaccination

          -  current acute illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph T Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Medical Outpatient Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Christoph Berger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

